Most simian-human immunodeficiency viruses (SHIVs) bearing envelope (Env) glycoproteins from primary HIV-1 strains fail to infect rhesus macaques (RMs). We hypothesized that inefficient Env binding to rhesus CD4 (rhCD4) limits virus entry and replication and could be enhanced by substituting naturally occurring simian immunodeficiency virus Env residues at position 375, which resides at a critical location in the CD4-binding pocket and is under strong positive evolutionary pressure across the broad spectrum of primate lentiviruses. SHIVs containing primary or transmitted/founder HIV-1 subtype A, B, C, or D Envs with genotypic variants at residue 375 were constructed and analyzed in vitro and in vivo. Bulky hydrophobic or basic amino acids substituted for serine-375 enhanced Env affinity for rhCD4, virus entry into cells bearing rhCD4, and virus replication in primary rhCD4 T cells without appreciably affecting antigenicity or antibodymediated neutralization sensitivity. Twenty-four RMs inoculated with subtype A, B, C, or D SHIVs all became productively infected with different Env375 variants-S, M, Y, H, W, or F-that were differentially selected in different Env backbones. Notably, SHIVs replicated persistently at titers comparable to HIV-1 in humans and elicited autologous neutralizing antibody responses typical of HIV-1. Seven animals succumbed to AIDS. These findings identify Env-rhCD4 binding as a critical determinant for productive SHIV infection in RMs and validate a novel and generalizable strategy for constructing SHIVs with Env glycoproteins of interest, including those that in humans elicit broadly neutralizing antibodies or bind particular Ig germ-line B-cell receptors.
HIV/AIDS | SHIV | CD4 | HIV-1 envelope S imian-human immunodeficiency viruses (SHIVs), which express the envelope of HIV-1 within the context of simian immunodeficiency virus of macaque (SIVmac) structural and regulatory elements, have broad potential applications for HIV/AIDS vaccine, treatment (cure), and pathogenesis research (1, 2) . SHIVs have been used to assess the protective effects of neutralizing or antibody-dependent cell-mediated cytotoxicity conferring antibodies (3) (4) (5) (6) (7) , the elicitation of broadly neutralizing antibodies (bNAbs) (8) (9) (10) (11) , the efficacy of broadly neutralizing monoclonal antibodies (mAbs) in preclinical trials with suppressive and curative intent (12, 13) , and virus-host interactions underlying virus transmission, immunodeficiency, and neurocognitive impairment (1, (14) (15) (16) (17) (18) (19) (20) (21) (22) . Despite these varied and important applications of SHIVs to HIV/ AIDS research, it is widely recognized that most SHIVs developed thus far have significant shortcomings as a model system for HIV-1 infection of humans (reviewed in ref. 1) . These limitations are often related to properties of the envelope (Env), which in most SHIVs does not faithfully reflect primary HIV-1 strains or transmitted/founder (T/F) viruses (23, 24) . HIV-1 Env, and its counterparts in naturally infected chimpanzees (SIVcpz) and gorillas (SIVgor), have evolved over millennia to infect great ape and, more recently, human CD4 T cells, but not CD4 T cells of lower primates, including Indian rhesus macaques (RMs; Macaca mulatta) (25) (26) (27) . Thus, most HIV-1 Envs do not bind Macaca spp. CD4 efficiently. Overbaugh and coworkers (26) provided a partial molecular explanation for this inefficiency by identifying a distinguishing Significance Simian-human immunodeficiency viruses (SHIVs) are an invaluable tool for assessing HIV-1 vaccines, developing therapeutic "cure" strategies, and understanding viral immunopathogenesis. However, only limited success has been achieved in creating SHIVs that incorporate HIV-1 envelopes (Envs) that retain the antigenic features of clinically relevant viruses. Here we focus on a critical residue of the CD4-binding region, Env375, which is under strong positive selection across the broad range of primate lentiviruses. We find that genotypic variation of residue 375 allows for the creation of pathogenic SHIVs that retain the antigenicity, tier 2 neutralization sensitivity, and persistence properties characteristic of primary HIV-1 strains. Taken together, our findings suggest a new paradigm for SHIV design and modeling with important applications to HIV-1 vaccine, cure, and pathogenesis research.
polymorphism at position 39 in rhesus and pigtailed macaque CD4 compared with human CD4. By necessity, then, SHIVs developed thus far contain HIV-1 Envs derived from one of four sources: (i) laboratory-adapted CXCR4-tropic HIV-1 strains (28); (ii) viruses passaged in vitro so as to acquire Env adaptations necessary for efficient infection of rhCD4 T cells, but at the cost of reduced conformational masking and protection from antibody neutralization (29) (30) (31) ; (iii) in vivo passaged and adapted virus swarms or clones (14, 15, (17) (18) (19) (20) (21) (32) (33) (34) ; or (iv) random screens of primary HIV-1 strains for rare viruses that encode Envs that fortuitously bind rhCD4 and allow for rhesus cell entry and replication (35) (36) (37) (38) .
The construction and development schemes of SHIVs have also been complicated. Many SHIVs derive from the original SHIV-HXBc2 construction of Sodroski and coworkers where HIV-1 HXBc2 tat, rev, and env sequences were subcloned into SIVmac239 (28, 39, 40) . SHIV-HXBc2 was further modified by substitution of the env gene from the dual CCR5/CXCR4 tropic HIV-1 89.6 strain, followed by additional passages in RMs, resulting in a highly pathogenic CXCR4 tropic phenotype (14, 15, 20) . Henceforth, a molecular clone (SHIV-KB9) of this strain served as a preferred backbone for SHIV constructions, including four recent reports (35) (36) (37) (38) . Other SHIV constructions have been similarly complicated (9, 18, 21, 29, 30, 32, 33) .
We took a different approach to SHIV design based on the hypothesis that a critical determinant of successful SHIV replication in RMs is efficient binding of Env to rhCD4. We further surmised that optimization of the SIVmac backbone and simplification of the HIV-1 insert strategy would enhance the chances of success. Our strategy was thus to: (i) molecularly clone a new SIVmac251-derived T/F virus, pSIVmac766 (41, 42) , that lacked any of four mutations found in SIVmac239 known to be suboptimal for replication (39, 43) ; (ii) substitute into this vector complete tat-rev-vpu-env (gp160) cassettes of T/F or primary HIV-1 strains; and (iii) modify Env residue 375, which is part of the CD4-binding pocket and facilitates CD4 engagement (44) , to encode genotypic variants (Met, M; Tyr, Y; His, H; Trp, W; and Phe, F) found naturally at this position across the broad evolutionary spectrum of primate lentiviruses (25) (www.hiv.lanl.gov/) (Fig. S1A ). Here we engineer and test six new SHIVs containing Env glycoproteins from primary or T/F strains of HIV-1 subtypes A, B, C, and D, each containing six different Env375 variants. We then describe a vector platform and refinements to the design strategy that can streamline the development of next-generation "designer SHIVs."
Results
Selection of Env Residue 375. HIV-1 Env binding to the CD4 receptor involves multiple structural rearrangements as Env transitions from a prefusion closed state (45) , through a single CD4-bound intermediate (46) , to a more fully engaged Env trimer capable of recognizing the coreceptor (47) . Although CD4 39I is the critical alteration in rhCD4 impeding HIV-1 Env binding (Fig. S2A ) (26) , the corresponding residue in huCD4 (39N) does not actually interact directly with HIV-1 Env, either in the prefusion closed state or in the CD4-bound state (48) (Fig. S2 B-E) . Instead, it lies proximal to the critical phenylalanine 43 (Phe-43) residue, which makes contact with Env residues in the Phe-43 binding pocket (48) . In rhCD4, modeling suggested that 39I could subtly alter the angle of the Phe-43 binding loop (Fig. S2G) .
Because structural rearrangements in HIV-1 Env associated with CD4 binding can be affected by large alterations in side-chain volume, we analyzed SIV and HIV-1 group M Env residues proximal to CD4 in the ligand-bound conformation for differences in amino acid volume (Fig. S1B) . We observed large differences at two sites: residue 375, where a Ser in HIV-1 corresponds to a larger, generally hydrophobic amino acid in SIVs (Fig. S1B) ; and residue 458. Of these, Env375 is closer to residue 43 of CD4 in both prefusion closed and CD4-bound conformations (Fig. S2 B and C). Moreover, in the HIV-1 YU2 backbone, a 375W substitution for 375S allows Env to more readily sample CD4-bound conformations and enhances its affinity for human CD4 (25, 44, 49, 50) . These findings, along with phylogenetic evidence of positive evolutionary selection at Env375 (Fig. S1A ), suggested to us that substitution of Env375S by residues containing larger hydrophobic or basic, space-filling side chains (e.g., M, Y, H, W, or F) might enhance rhCD4 binding and SHIV replication in RMs.
SHIV Design. We cloned a replication-competent, pathogenic T/F provirus designated SIVmac766 (Fig. 1A ) from a RM infected by atraumatic rectal inoculation with an early passage isolate of SIVmac251 (41, 42) . Complete tat-rev-vpu-env(gp160) cassettes from a prototypic primary subtype B strain YU2 (51) and from a genetically divergent T/F subtype D HIV-1 strain 191859 (52) were exchanged for the corresponding region of SIVmac766 ( Fig. 1 B and C) . Site-directed mutagenesis was used to modify Env residue 375 from Ser to Met, Tyr, His, Trp, or Phe in each env. In subsequent SHIV designs, we incorporated a carboxy terminal gp41 tail exchange of 58 amino acids of SIVmac766 gp41 for the homologous 33 amino acids of HIV-1 (SHIV.D.191859.dCT in Fig.  1D and Fig. S3 ), because this substitution occurred spontaneously in infected RMs and enhanced SHIV replication in vitro and in vivo (see below).
We used a similar design strategy to exchange all or portions of tat-rev-vpu-env(gp160) from other T/F HIV-1 strains into the SIVmac766 backbone, but a number of these constructs failed to generate infectious virus. We attributed this inconsistency to differences in the reading-frame organization of different HIV-1 inserts relative to the SIVmac766 vpr/tat overlap, resulting in untoward effects on RNA splicing and protein expression or to strain-specific differences in HIV-1 Tat or gp41, which must interact with cognate motifs of SIVmac766 (i.e., the RNA TAR element and Gag matrix protein, respectively). To avoid these potential complicating factors and to develop a more consistent and reliable strategy for generating SHIVs with a high likelihood of replicative success, we refined our approach to exchange just the HIV-1 vpuenv(gp140) or env(gp140) cassettes into the highly infectious and replicative prototypic clone SHIV.D.191859.dCT ( Fig. 1 D and E and Fig. S3 ). Importantly, this construction scheme allowed for the exchange of complete gp120 and gp41 extracellular and membrane spanning domains, which contain the epitopes for all neutralizing antibodies (NAbs). This strategy was used to generate SHIVs containing vpu-env(gp140) sequences from T/F HIV-1 subtype C strains CH505 and CH848 (53) and T/F subtype A strain BG505 (54) . These three viruses were of particular interest because they represented additional HIV-1 subtypes, had elicited bNAbs in their respective human hosts (53, 54) , and included the widely studied preclinical vaccine strains CH505 and BG505 (53, 55, 56) . For all SHIVs ( Fig. 1 B- In every instance, virions were efficiently produced, generally in the range of ∼10 10 virions per mL, as determined by quantification of vRNA by real-time RT-PCR or p27 antigen by ELISA (Dataset S1). All 36 SHIVs were highly infectious in TZM-bl cells, which bear huCD4 and huCCR5 on their surface (61), with infectivity to particle (I:P) ratios of 0.001-0.00002. When grown in primary rhCD4 T cells, these same SHIVs with favorable Env375 substitutions reached I:P ratios as high as 0.02 when titered in TZM-bl cells and 0.0006 in primary, activated rhCD4 T cells (Dataset S1).
We tested the effects of Env375 variation on the binding of Env to human and rhesus CD4 by three different methods. The first assay examined the ability of soluble rhCD4-Ig or huCD4-Ig to bind the functional Env trimer on infectious SHIVs and inhibit virus entry into TZM-bl cells ( Fig. 2A) . Overall, B.YU2 Env375S was substantially more sensitive to huCD4-Ig and rhCD4-Ig than were wild-type Env375S alleles from the other SHIVs, which is consistent with previous studies showing that YU2 Env-huCD4 affinity is high, thereby allowing it to use low levels of CD4 on human T cells, macrophages, and microglia for entry (25, 44, 50, 62) . A rank order of SHIV sensitivity to huCD4-Ig and rhCD4-Ig was B.YU2 > D.191859 > C.CH505 > C.CH848 > A.BG505.332N and A.BG505.332T. For any particular Env375 substitution in any of the Env backbones, huCD4-Ig neutralized SHIVs at ∼100-fold lower concentrations than did rhCD4-Ig, indicating a substantially higher Env affinity for huCD4 than for rhCD4. Envs containing the wild-type 375S residue were least sensitive to rhCD4-Ig or huCD4-Ig entry inhibition. Substitutions at Env375 led to increased sensitivity to rhCD4-Ig and huCD4-Ig inhibition by rank order W,Y > H,F > M > S. As a group, Envs bearing the 375 Y, W, H, or F residues were ∼10-to 100-fold more sensitive to rhCD4-Ig and huCD4-Ig than were Env375S or Env375M. Analyses using soluble huCD4 and rhCD4 gave similar results. These findings indicate that substitution of nonpolar aliphatic, bulky hydrophobic, or basic aromatic amino acids at Env375 substantially increases the affinity of the functional HIV-1 Env trimer for rhesus and human CD4.
We next analyzed whether Env375 mutations affected the binding and entry of SHIVs in cells expressing rhesus or human CD4 on their surface (Fig. 2B) . A canine cell line, ZB5, stably transduced to express rhCD4 and rhCCR5 at levels comparable to huCD4 and huCCR5 on TZM-bl cells, was used to assess SHIV binding and entry. In ZB5 cells, SHIV B.YU2 was the only wild-type 375S variant capable of achieving significant levels of infectivity. This result correlated with the enhanced affinity of the SHIV B.YU2 Env375S allele for soluble rhCD4-Ig ( Fig. 2A) . The 375M substitution in all six SHIV backbones had either no effect or increased virus infectivity modestly (twofold to fourfold) (Fig. 2B ). This result again correlated with the unchanged or modestly enhanced sensitivity of the Env375M allele to soluble rhCD4-Ig ( Fig. 2A) . In contrast, the 375Y/H/W/F substitutions increased virus infectivity in ZB5 cells markedly (10-to 1,000-fold) in all SHIV Env backbones except B.YU2, where the effect was more modest. Overall, a general trend was observed between enhanced entry of SHIV Env375 variants into ZB5 cells and enhanced sensitivity to entry inhibition by soluble rhesus CD4-Ig, although this correlation was imperfect. These findings suggested that a threshold for SHIV Env-rhCD4 binding must be reached in order for virus infection to occur, but that additional postbinding events contribute to efficient virus entry and replication (see below).
As a third measure of Env-CD4 binding, we tested by surface plasmon resonance (SPR) the affinity of rhCD4-Ig and huCD4-Ig for monomeric HIV-1 Env gp120 containing each of the six Env375 variants and expressed in 293F cells. (Dataset S2) . In all cases, HIV-1 Envs had higher affinity for huCD4 than for rhCD4, and substitution of 375S by 375M, 375H, 375Y, 375F, or 375W led to higher binding affinity to human and rhesus CD4.
Neutralization Sensitivity of SHIVs with Env375 Mutations. We performed a comprehensive analysis of the sensitivity of all 36 SHIVs to a large panel of neutralizing mAbs, polyclonal anti-HIV antibodies in patient sera, and the entry fusion inhibitor T1249. The objective was to determine whether amino acid substitutions at residue 375 altered Env antigenicity, neutralization sensitivity, or fusion efficiency. As controls, we analyzed the corresponding HIV-1 Envs containing the wildtype 375S residue expressed from full-length T/F HIV-1 proviral genomes or as Env pseudotypes. In all six SHIV Env backbones, there were little or no appreciable effects of residue 375 substitutions on antigenicity or neutralization sensitivity for any mAb or immune plasma tested (Fig. 3 and Fig. S4 ). This result included as many as six different CD4bs mAbs (b12, VRC01, 3BNC117, NIH 45-46 G54W, CH103, and CH31); seven V1V2 mAbs (PG9, PG16, PGDM1400, PGT145, CH01, VRC26.08, and VRC26.25); four V3 high mannose patch mAbs (PGT121, PGT126, PGT128, and 2G12); a gp120/gp41 interface mAb (8ANC195); membrane proximal external region (MPER) mAbs (4E10, 10E8, and 2F5); V3 epitope directed mAbs (3869, 3074, and 447-52D); and CD4-induced (CD4i) mAbs (17b, 21c, and 19e). There were also no effects of Env375 substitutions on sensitivity to T1249, which indirectly assesses fusion efficiency (63) . Importantly, we observed that the V3 and CD4i mAbs (64) did not neutralize any of the wild type SHIVs or their Env375 variants aside from modest activity against B.YU2 ( Fig. 3 and Fig. S4 ). These findings, together with the consistent neutralization patterns of the other mAbs shown in Fig. 3 and Fig. S4 , including V1V2 mAbs that recognize quaternary epitopes, are strong indications that the 36 SHIVs retain native-like Env trimer conformations and intact conformational masking (65) .
For most SHIV -antibody combinations, we observed IC 50 values very similar to the corresponding wild type HIV-1 Envs. The exceptions were enhanced SHIV.B.YU2 and SHIV.D.191859 sensitivity to mAbs 4E10, 2F5, 10E8, and 8ANC195. These differences may reflect the fact that the carboxy terminus of gp41 in SHIVs B.YU2 and D.191859 ( Fig. 1 B and C and Fig. S3 ) is of HIV-1 origin and must interact with the Gag matrix of SIVmac766, whereas for the HIV-1 controls the carboxy terminus of gp41 and the Gag matrix are both of HIV-1 derivation. This gp41-Gag matrix mismatch was not a confounding factor for SHIVs A.BG505.332N.dCT, A.BG505.332T.dCT, C.CH505.dCT or C.CH848.dCT because they contain chimeric Envs where the carboxy terminus of gp41 is of SIVmac766 derivation ( Fig. 1E and Fig. S3 ). We show below that SHIVs containing an SIVmac gp41 terminus have higher Env:Gag ratios, higher I:P ratios, and higher replication rates in rhCD4 T cells compared with SHIVs that contain an HIV-1 gp41 terminus. Thus, the gp41-Gag matrix mismatch for SHIVs B.YU2 and D.191859 (but not for the other SHIVs) may alter slightly the per virion number and geometry of the Env trimer complex as it is tethered to the virus membrane or retard virus fusion sufficiently to allow for greater neutralization activity to be exerted by MPER and gp120/gp41 interface mAbs.
Replication of SHIVs in Human and Rhesus CD4 T Cells. Env375 variants of SHIVs B.YU2, D.191859, C.CH505.dCT, C.CH848.dCT, A.BG505.332N.dCT, and A.BG505.332T.dCT were tested for replication in primary, activated human and rhesus CD4 T cells (Fig. 4) . All 36 SHIVs replicated in human cells efficiently with the wild-type Env375S generally equaling or exceeding other Env375 variants. This result is not surprising, because Env375S is the residue found most commonly in HIV-1 group M strains (Fig. S1 ). In contrast, the Env375 variants exhibited very different patterns of replication in rhCD4 T cells. For SHIVs D.191859, C.CH505.dCT, C.CH848.dCT, A.BG505.332N.dCT, and A.BG505.332T.dCT, replication of the wild type Env375S variant was very low or undetectable (Fig. 4) . For SHIV.B.YU2, the 375S variant replicated comparably with the other Env375 variants. The Env375M variant of SHIVs B.YU2 and D.191859 (but not of C.CH505.dCT, C.CH848.dCT, A.BG505.332N.dCT, and A.BG505.332T.dCT) also replicated well in rhCD4 T cells. In all six SHIV Env backbones, the 375Y/H/W variants replicated well in rhCD4 T cells, generally to levels comparable to those observed in huCD4 T cells, whereas Env375F replication was variable. Thus, there was a good overall correlation among the different SHIV Env375 variants for enhanced binding to rhCD4 (Fig. 2 A and C and Dataset S2), enhanced entry into cells bearing rhCD4 on their surface (Fig. 2B) , and enhanced replication in primary activated rhCD4 T cells (Fig. 4) .
Replication of SHIVs in RMs. Given the encouraging in vitro replication data, we inoculated a total of 24 RMs with SHIVs by intravenous or intrarectal routes (Fig. 5) . Because we were initially uncertain of the likelihood of productive infection, we depleted a subset of RMs To determine which Env375 variants best supported virus replication in the SHIV.D.191859 and SHIV.B.YU2 backbones, we performed deep sequencing by Illumina MiSeq (Fig. 5F ) and a genome-wide analysis by single genome sequencing (SGS) (Fig.  S5A) (66) . MiSeq analysis at a depth of >2,500 vRNA sequences showed that both SHIV.D.191859-inoculated animals were initially infected by SHIVs bearing Env375M, -Y, -H, and -F, but not by Env375S or -W (Fig. 5F ). Env375M replicated preferentially in both animals at weeks 3, 10, and 20 after infection. In SHIV.B.YU2-inoculated animals, all six Env375 variants led initially to productive infection, although Env375S, and to a lesser extent Env375M, replicated preferentially at all time points (Fig. 5F ). SGS confirmed and extended these findings, demonstrating that sequence variation at weeks 2 and 4 after infection was essentially random across the entire genome, aside from preferential replication of Env375M, -Y, -H, and -F variants (Fig. S5A) . The SGS data thus make the important point that during the initial 4-wk period of infection when virus replication is maximal, there is no apparent virus adaptation or selection besides that involving the Env375 substitution. This finding means that SHIV D.191859.Env375M, -Y, -H, -F variants are well fit from the outset and do not require any additional mutations across their entire 9-Kb genomes to achieve efficient replication in RMs. By week 10, there was evidence of strong selection for Env375M with additional nonsynonymous mutations in Tat and Nef (RM131) and Vpx, Vpr, and Nef (RM138) corresponding to known or predicted cytotoxic T-cell epitopes (Fig. S5A) .
A striking finding in the week 10 and 20 sequences of both RM131 and RM138 was a highly selected deletion of 104-125 nt of the carboxy terminus of HIV-1 gp41, including an 11-nt multiple cloning site used to introduce the HIV-1 tat-rev-vpu-env cassette (Fig. S5A ). This deletion led to an in-frame juxtaposition of the corresponding gp41 carboxy terminus of SIVmac766 encoded in the nef overlap (Fig. S3) . A 14-to 19-nt deletion of the multiple cloning site at the 5′ junction of the HIV-1 tat-rev-vpu-env cassette also occurred. Similar, but smaller and less prevalent, deletions occurred in plasma viral sequences from RM72 and RM74. We hypothesized that the substitution of the SIVmac766 gp41 carboxy terminus for the corresponding region of HIV-1 Env contributed to the persistent high-level replication observed in the two SHIV.D.191859-infected animals by enhancing Env gp41-Gag matrix interactions and leading to higher virion Env content, higher I:P ratios, and enhanced virus replication. We found support for this hypothesis by showing that virion Env:Gag ratios were elevated by 1.5-to 2.5-fold (Fig. S5B ), I:P ratios were increased by 37-to 100-fold (Dataset S1), and replication in human and rhesus CD4 T cells was increased by at least 10-fold (Fig. S5C ) in SHIV.D.191859.dCT (Fig. 1D) , compared with SHIV.D.191859 (Fig. 1C) . Similar in vivo adaptations have been seen previously in other SHIVs that contained redundant HIV-1 and SIVmac239 gp41 carboxy-terminal coding sequences (20) . Next, we tested directly the replication fitness advantage afforded to SHIV.D.191859 by the SIV/HIV gp41 tail exchange and the Ser-to-Met substitution at Env375 and, in the same experiment, the effects of intravenous vs. intrarectal virus inoculation and CD8 + T-cell depletion (Fig. 5B) . Thus, we inoculated six non-CD8-depleted RMs by intravenous (n = 2 RMs) or intrarectal (n = 4 RMs) routes with SHIV.D.191859 containing an equal mixture of Env375M.dCT, Env375S.dCT, Env375M (without dCT), and Env375S (without dCT). All RMs became infected after a single inoculation. Early viral replication kinetics were similar between animals infected by intravenous vs. intrarectal routes. Peak virus titers occurred at day 17 in both groups of animals and were indistinguishable in magnitude (range: 1.8 × 10 6 to 1.3 × 10 7 vRNA copies per mL; mean ± SEM: 6.0 × 10 6 ± 1.9 × 10 6 ). Setpoint viremia titers were ∼100-fold higher in animals that were subjected to CD8 + cell depletion (Fig. 5A ) compared with nondepleted animals (mean: 4.9 × 10 5 vs. 4.3 × 10 3 ; P < 0.0001) (Fig. 5B) . SGS was used to determine which Env alleles replicated preferentially 3 wk after infection by intravenous and intrarectal routes in the non-CD8-depleted animals. All six animals showed an essentially identical pattern of selection: Of a total of 210 env sequences analyzed, 210 contained the SIV-for-HIV gp41 carboxy terminal tail substitution, and 209 of 210 sequences contained Env375M (Fig. 5G) . Otherwise, sequence variation was again random across the complete Env gp160 and 3′ half genome. Taking these data together, we found that in eight animals infected with Env variants of SHIV.D.191859, there was strong selection favoring replication of SHIV.D.191859.375M.dCT and no evidence of early virus selection otherwise. For this reason, as well as the persistent replication kinetics for >1 y, SHIV.D.191859.375M.dCT (Fig. 1D ) was selected as a new molecular platform for further SHIV constructions, which included Envs from C.CH505, C.CH848, and A.BG505 (Fig. 1E) .
Fig. 4. Replication of SHIV Env375 variants in primary human and rhesus CD4 T cells. Imput virus was normalized by p27Ag (SI Materials and Methods
Four CD8 T-cell-depleted RMs were inoculated intravenously with a SHIV.C.CH505.dCT.Env375 pool (Fig. 5C ) and four others with a SHIV.C.CH848.dCT.Env375 pool (Fig. 5D ). All eight animals became productively infected and exhibited indistinguishable early viral replication kinetics. One animal (RM6073) infected by SHIV.C.CH505.dCT died 3 wk after infection from an unrelated allergic event; a second SHIV.C.CH505-infected animal (RM6070) was euthanized at 36 wk after infection because of a rapidly progressive AIDS-defining high-grade lymphoma, and a third SHIV.C.CH505-infected animal (RM6069) was euthanized at 40 wk after infection with wasting, weight loss, rhesus cytomegalovirus (RhCMV) colitis, and Pneumocystis carinii pneumonia (PCP), all AIDS-defining conditions. Two animals (RM6161 and RM6024) infected by SHIV.C.CH848 developed AIDS with wasting, weight loss, RhCMV colitis, anemia, and thrombocytopenia 10 and 14 wk after infection and were euthanized. The other animals remained healthy through the latest follow-up time points (52 and 36 wk, respectively) and had lower viral load setpoints than did animals that progressed to AIDS. To determine which Env375 variants supported preferential virus replication in vivo, we performed MiSeq analyses on plasma vRNA 2-10 wk after infection. In SHIV.C.CH505-infected animals, Env375Y, H, W, and F comprised nearly 100% of the circulating virus at 2 wk, but by 10 wk, Env375H predominated at 87-99%, with minor fractions of 375Y and 375F (Fig. 5H) . In SHIV.C.CH848-infected animals 4 wk after infection, Env 375H predominated at 54-80% with the remainder comprising nearly entirely 375W (Fig. 5I) .
Finally, we inoculated six non-CD8-depleted animals intravenously with a SHIV.A.BG505.332T.dCT Env375 pool (n = 2 RMs), a SHIV.A.BG505.332N.dCT Env375 pool (n = 2 RMs), or an equal mixture of all 12 SHIV variants (n = 2 RMs). All six animals became productively infected and exhibited similar acute viral replication kinetics (Fig. 5E) . Peak viral loads ranged from 9.6 × 10 5 to 7.2 × 10 7 vRNA copies/mL, and at 8 wk after infection, viral loads ranged from 6.62 × 10 2 to 1.1 × 10 6 vRNA copies/mL Animal RM6447, with the highest setpoint virus load, developed wasting, weight loss, pancytopenia, RhCMV reactivation, colitis, and PCP, necessitating euthanasia at week 9, whereas the other five animals remained clinically healthy through the most recent sampling time point at week 12. In all six animals, Env375Y replicated most efficiently (83-95%) followed by Env375W (3-15%) (Fig. 5J) . Interestingly, in the two RMs inoculated with SHIVs containing both Env332T and Env332N, the two variants replicated nearly equally in the initial 4 wk, indicating that there is no fitness advantage associated with the gain or loss of this antigenically important site within the BG505.Env375Y background.
Immunopathogenesis of SHIV Infections. In total, we studied SHIV infections in 24 RMs: 12 with CD8 depletion and 12 without. Six CD8-depleted animals developed AIDS, compared with one non-CD8-depleted animal (P < 0.05), and all were euthanized and necropsied (Figs. S6 and S7 and Datasets S3 and S4). Three animals died of AIDS within 3 mo of infection (RM6424, RM6161, and RM6447) and were considered "rapid progressors" (67) . One of these animals, RM6447, is notable because it was not subjected to CD8 T-cell depletion before virus inoculation. All three rapid progressors had evidence of multiorgan RhCMV disease (Dataset S4), with RM6447 also demonstrating PCP (Fig. S6D) . Two animals (RM6069 and RM6070) died at 9 mo after infection and two others at 15 and 21 mo (RM138 and RM131), which is more typical of SIV infection (34, 67) . All four of these latter animals had AIDSdefining conditions, including wasting, weight loss, multiorgan RhCMV disease, PCP or atypical mycobacterial infection (Figs. S6 and S7 and Dataset S4). We obtained virus isolates from terminal peripheral blood mononuclear cell samples from all seven animals that died with AIDS to characterize virus coreceptor use. In each case, R5 tropism was retained (Fig. S8) . Peripheral blood CD4 and CD8 T-cell counts, along with effector memory, transitional, central memory, and naïve subsets, were assessed in all 24 RMs (Dataset S3). Animals that developed AIDS exhibited greater declines in absolute CD4 T-cell counts, CD4/CD8 ratios, and CD4 Tem populations compared with animals that did not develop AIDS. At their terminal blood draw, animals that developed AIDS had marked depressions in all CD4 T-cell subsets. Analysis of gut-associated lymphoid tissue (GALT) revealed early and sustained loss of lamina propria CD4 T cells and marked GI tract pathology, including GI tract damage evidenced by enteritis/ colitis, neutrophil infiltration, crypt abscesses, crypt and villus blunting, and, in one case, infiltration with foamy macrophages, a lesion characteristic for atypical mycobacteria infection (Figs. S6 and S7 and Dataset S4). Analysis of lymph nodes revealed pathology associated with either asymptomatic SIV disease, such as follicular hyperplasia with confluent germinal centers, or lesions characteristic of classic progressive HIV/SIV disease, including CD4 T-cell loss, lymph node fibrosis, and follicular involution and depletion associated with amyloid deposits in the germinal centers. Necropsy findings in the seven animals that died with AIDS also included interstitial pneumonia, lymphoid infiltrates around trachea and bronchioles, glomerulonephritis and glomerulosclerosis, lymphoid infiltrates in the kidney cortical and medullary areas, well-defined granulomas in the liver consistent with atypical mycobacterial infection, and inflammatory infiltrates around portal and central veins (Figs. S6 and S7 and Dataset S4).
Western blot immunoreactivity to core and Env proteins was assessed at 4 and 10 wk after infection, corresponding to a time frame that in humans is associated with anti-HIV-1 antibody seroconversion (68) . Western blot reactivity to diagnostic Env and Gag proteins was strongly positive in all but three animals (RM195, RM6424, and RM6161) (Dataset S3). Two of these animals had entirely negative Western immunoblots, which was associated with high peak and setpoint plasma virus titers and accelerated death due to AIDS at weeks 10 and 14. Similar findings have been reported in a subset of SIV-infected RMs (67) and in rare human HIV-1 infections (69). Anti-SIVp27 binding antibody titers were assessed at weeks 10 and 32 after infection. Results were strongly reactive for all animals, except RM6424 and RM6161 (Dataset S3). NAb responses were assessed in 13 RMs with at least 4 mo followup postinfection against a standardized global panel of tier 1 (n = 3) and tier 2 (n = 17) virus strains corresponding to HIV-1 subtypes A, B, C, D, and circulating recombinant-form CRF01_AE (Dataset S5) (70, 71) . Among SHIV D.191859-infected (n = 8), B.YU2-infected (n = 2), and C.CH505-infected (n = 3) animals, 12 of 13 had reciprocal autologous NAb titers (IC 50 ), ranging from 25 to 7,911 (Datasets S3 and S5). There was a statistically significant positive correlation between viral load setpoint and maximum autologous NAb titer (Spearman r s = 0.7, P < 0.05). Among 10 SHIV D.191859-or B.YU2-infected animals that were sampled for >1 y, 10 had reciprocal plasma IC 50 NAb titers to three heterologous tier 1 viruses ranging from 34 to >43,740; 10 had titers against at least one heterologous tier 2 virus, three animals neutralized two heterologous tier 2 viruses, and one or more animals neutralized four, five, or seven heterologous tier 2 viruses. Reciprocal IC 50 NAb titers against heterologous tier 2 viruses were generally low, ranging from 20 to 557.
Discussion
Overbaugh and coworkers recently reviewed the history of SHIV development, the limitations of current SHIVs, and the still largely unrealized potential of SHIVs to advance vaccine, cure, and pathogenesis research (1) . They, along with other authors (35) (36) (37) (38) , concluded that a paramount objective continues to be the development of pathogenic SHIVs that encode env sequences from circulating T/F HIV-1 variants and establish persistent infection without passage or adaptation in macaques. The present report goes a long way toward reaching this goal.
We prospectively identified six primary HIV-1 Envs for SHIV development. In each case, we were successful in constructing SHIVs that replicated well in RMs with plasma viral load kinetics (Fig. 5 ) remarkably similar to acute and early chronic HIV-1 infection in humans (72, 73) . In other recent studies, we created a seventh SHIV, this one from a T/F HIV-1 subtype C virus Ce1176 (74) , that is part of a widely used 12-member global neutralization panel developed by Montefiori, Seaman, and coworkers (71) . SHIV.C.Ce1176 replicated efficiently in primary human and rhesus CD4 T cells in vitro and productively infected five of five non-CD8-depleted RMs after intravenous challenge. Thus, using the strategy outlined in Fig. 1 , we have created seven consecutive SHIVs from primary or T/F subtype A, B, C, and D HIV-1 viruses that infect and replicate efficiently and persistently in RMs, in some cases leading to AIDS pathology and death. This finding contrasts with four recent reports (35) (36) (37) (38) that used a conventional KB9 SHIV design strategy (20) , where the vast majority of 91 SHIVs constructed from primary HIV-1 Envs failed to replicate efficiently or persistently in vivo. Not only is the success rate of the strategy described in the present report far higher, but it has the advantage of allowing for strategic, prospective targeting of desirable HIV-1 Envs for SHIV construction and analysis, which was highlighted in the present study by SHIVs containing T/F Envs corresponding to HIV-1 CH505 (53, 55, 75) , CH848, and BG505 (54, (57) (58) (59) (60) , all of which evolved in their human hosts to elicit bNAbs. The SHIVs described herein also exhibit particularly favorable biological and antigenic properties that distinguish them from most previously described SHIVs (3, 9, 18, 21, 29-33, 35-38, 76) . Specifically, they exhibit sensitivity to a wide spectrum of broadly neutralizing mAbs that target the five principal sites of bNAb recognition (77, 78) , while retaining effective conformational masking typical of primary or T/F virus strains (23, 65) .
If substitution of Env375 with variant residues is the sine qua non of our SHIV design strategy, what, then, is the mechanistic basis for enhanced rhCD4 binding and cell entry? The native, unliganded HIV-1 Env trimer is conformationally flexible or "metastable" (25, 44, 49, 50, (79) (80) (81) , and movement of the Env trimer from its unliganded state to the CD4-bound conformation must be carefully regulated, because premature triggering of the unliganded glycoprotein complex to downstream conformations results in functional inactivation (82, 83) . Structural and molecular biological studies have revealed a "layered" inner domain gp120 architecture that facilitates movement among alternative Env conformations required for virus entry (25, 50, 80, 84) . Env gp120 refolds itself upon binding CD4, with the inner, outer, and bridging sheet domains brought into proximity at the interface with CD4. This process creates a ∼150-Å 3 cavity between HIV-1 gp120 and CD4 bounded by Phe-43 of CD4, which makes numerous contacts with conserved gp120 residues, although Env375 is not one of them (48, 85) . Env375 does, however, abut the Phe-43 cavity, as do other highly conserved residues, many of them containing aromatic side chains. These Phe-43 cavity-lining residues contribute to an aromatic array that helps stabilize the CD4-bound conformation. Substitution of Env375W for Env375S in HIV-1 YU2 gp120 fills the Phe-43 cavity and allows the glycoprotein to sample conformations closer to the CD4-bound state spontaneously (25, 44, 50, 84) . This process leads to enhanced affinity for CD4, largely due to a decrease in the off-rate of the bound Env-CD4 complex (50) . We hypothesized that substitution of the naturally occurring HIV-1 Env375S by certain larger space-occupying side chains would enhance Env gp120 binding to rhesus CD4 and facilitate virus entry in rhesus cells in a similar manner. Molecular modeling of HIV-1 gp120 in complex with human and rhesus CD4 (Fig. S2) , together with three independent lines of empirical evidence-neutralization of infectious virus by soluble rhCD4 (Fig. 2A) , entry of virus into rhCD4-bearing target cells (Fig. 2B) , and direct analysis of Env binding to rhCD4 by SPR (Fig. 2C) -support this hypothesis. Thus, we conclude that the mechanism by which the different SHIV Env375 amino acid substitutions enhance rhCD4 binding is likely to be similar to that described for enhanced binding of the YU2 Env375W variant to human CD4 (25, 44, 50, 84) .
Factors contributing to successful replication of SHIV variants in rhesus cells in vitro and in vivo, however, likely extend beyond the initial binding event of Env to rhCD4. One of these factors is the "intrinsic reactivity" or "responsiveness" of Env to CD4 engagement, which reflects the product of CD4 binding and downstream consequences of CD4 binding that allow the Env glycoprotein to negotiate transitions to lower-energy states, including those responsible for cell entry (25, 44, 50, 80, 82, 84, 86, 87) . Env responsiveness to CD4 influences the ability of HIV-1 to infect cells with different levels of CD4 (e.g., macrophages) or variants of CD4 (e.g., CD4 from other species) and the sensitivity of HIV-1 to sCD4. The responsiveness of HIV-1 to CD4 can be altered by generic changes in Env, which also affect the sensitivity of the virus to antibody neutralization (31), or by more selective changes, as in the case of Env375 variants. We hypothesized that SHIVs must attain a certain level of Env responsiveness to rhCD4 to infect RM CD4 T cells and replicate efficiently in vivo, but without leading to abortive downstream conformations that prevent infection. A corollary is that, because natural HIV-1 Env variants exhibit different levels of CD4 responsiveness, different degrees of compensation conferred by changes in residue 375 will be required for optimal adaptation to rhCD4. To test these notions, we used the sensitivity of SHIVs containing wild-type Env375S to human and rhesus sCD4-Ig as an indicator of the baseline CD4 responsiveness and determined whether the size of residue 375 side chains contributing to efficient virus replication in rhCD4 T cells in vitro and in vivo correlated inversely. The answer was affirmative (Fig. 6) . The results shown support the hypothesis that to replicate efficiently in monkeys, SHIVs with lower baseline CD4 responsiveness, such as C.CH505, C.CH848, and A.BG505, require residue Env375 substitutions that result in proportionally greater CD4 responsiveness. Conversely, SHIVs with higher levels of baseline CD4 responsiveness (i.e., that exhibit greater sensitivity to sCD4), such as B.YU2 and D.191859, require residue Env375 substitutions that result in smaller changes in CD4 responsiveness. These observations suggest that a major force driving the selective replication of SHIV Env375 variants in RMs-375S for B.YU2, 375M for D.191859, 375H for C.CH505 and C.CH848, and 375Y for BG505.332T and BG505.332N-is the requirement to achieve both adequate rhCD4 binding and enhanced Env responsiveness to CD4 without altering other essential properties of the native Env trimer, including conformational masking and orderly downstream conformational changes leading to virus-cell membrane fusion.
Although CD8 depletion in half of the study animals limited our ability to fully evaluate the natural history and immunopathogenesis of SHIV infections, the findings from analysis of plasma viral load kinetics and peripheral blood T-cell subsets in all animals at multiple time points, biopsies of lymph nodes and GALT at early and late time points, and immunopathological examinations at necropsy, leave no doubt as to the pathogenicity of the Env375-modified T/F SHIVs. Plasma viral load kinetics in acute and early chronic phases of infection (Fig. 5) were nearly indistinguishable from human infection by HIV-1 (72, 73) . All CD4 T-cell subsets, not just CD4 naïve cells, underwent gradual decline; GALT was selectively depleted of CD4 T cells early in infection and did not recover; and R5 tropism of SHIVs did not change to X4 tropism, even in animals that died of accelerated AIDS within the first 3 mo of infection (Fig. S8) . AIDS-defining events included wasting, CD4 T-cell lymphopenia, pancytopenia, PCP, atypical mycobacterial infections, RhCMV reactivation and disease, and high-grade lymphoma (Dataset S4). Of note, the development of NAbs in SHIV-infected RMs resembled that in humans infected by HIV-1 with respect to kinetics, titers, breadth, and potency. In SHIV infections, autologous tier 2 NAbs developed in most RMs to reciprocal IC 50 titers between 25 and 8,000 in the first 3-6 mo of infection (Datasets S3 and S5), whereas heterologous tier 2 NAbs developed sporadically and generally to only low titers after 1 y of infection (Dataset S5). Further studies with additional SHIVs, larger numbers of infected animals, and longer follow-up periods will be needed to assess the similarities and differences in NAb responses in RMs and humans to viruses bearing primary HIV-1 Envs.
Designer SHIVs bearing selected amino acid substitutions at residue 375 can be an enabling tool for HIV vaccine and cure research. As challenge stocks for active and passive preclinical vaccines studies, we now have in hand well-pedigreed SHIVs that express primary or T/F subtype A, B, C, and D Envs. These SHIVs have been expanded in primary activated rhCD4 T cells in tissue culture to high titers (∼10 9 virions per milliliter) and exhibit high infectivity-to-particle ratios when measured on TZM-bl cells (∼0.01) and primary rhCD4 T cells (∼0.0005) (Dataset S1). They also transmit efficiently in vivo across mucosal surfaces, including rectal, penile (glans and foreskin), or vaginal without hormonal manipulation. This finding makes possible RM modeling of vaccine prevention against all of the principal routes of HIV-1 acquisition using SHIVs with biologically relevant Envs. Importantly, the SHIV C.CH505, C.CH848, D.191859, and A.BG505 challenge stocks contain no discernible in vitro adaptations that alter their native antigenicity or neutralization sensitivity, a problem that has plagued other SHIV challenge viruses (12, 29, 31-33, 35, 38) . With respect to immunogen design, by strategically targeting for SHIV construction primary or T/F HIV-1 Envs with unique properties such as the ability to bind unmutated common ancestor germ-line Ig receptors of human bNAb lineages [e.g., CD4bs bNAb lineages by HIV-1 CH505 (53, 55, 75) or V1/V2 bNAb lineages by HIV-1 CRF_AG_250, ZM233, WITO4160, and CAP256 (88, 89)] or to elicit bNAbs in humans [e.g., HIV-1 CH505, CH848, and BG505 (53) (54) (55) 75) ], critical questions regarding the inherent immunogenicity of particular Env glycoproteins, contributions of rhesus host genetics to the elicitation of NAbs and bNAbs, and the role of stochastic vs. deterministic events in antibody elicitation can be parsed. In this way, analysis of virus-antibody coevolution can potentially guide structure-based (56, 90, 91) or viral lineage-based (92, 93) immunogen design. Finally, further model development to document authentic HIV-1-like SHIV persistence and pathogenesis and susceptibility to suppression by combination antiretroviral therapy should set the stage for these viruses to facilitate the preclinical evaluation of HIV-1 Env targeted therapeutic interventions in the context of HIV-1 cure research.
Materials and Methods
Nonhuman Primates. Indian RMs were housed and studied at the University of Pittsburgh or Bioqual, according to the Association for Assessment and Accreditation of Laboratory Animal Care standards. Experiments were approved by the University of Pittsburgh and Bioqual Institutional Animal Care and Use Committees (SI Materials and Methods).
SHIV Constructions. The SIVmac766 clone (GenBank accession no. KU955514) was modified by replacing the SIV genome between the stop codon of vpr and start codon nef with a linker containing the unique restriction enzyme sites AgeI and AclI. A complete HIV-1 tat/rev/vpu/env(gp160) cassette was inserted (SI Materials and Methods).
SHIV Infection of Primary Rhesus and Human CD4 T Cells. SHIV stocks were generated in 293T cells. Virus imput was normalized to ∼1,000 virions (0.1 pg of p27Ag) per cell (SI Materials and Methods). SPR. Three HIV-1 Envs with residue 375 substitutions were analyzed, as described (SI Materials and Methods).
Virion-Associated Env:Gag Ratio Measurements. Virus was purified by filtration and density gradient centrifugation. Quantitative measurements of viral p27 (CA) and gp120 protein were performed by dual-color fluorescent protein gel analysis (41, 95) (SI Materials and Methods). Viral Sequencing. SGS and MiSeq sequences were generated as described previously (23, 66) (SI Materials and Methods).
Immunohistochemistry. Immunohistological stains were performed as described previously (96) .
Coreceptor Use. Coreceptor use was determined in TZM-bl cells by selective blockade using Maraviroc (CCR5), AMD3100 (CXCR4), or a mixture of inhibitors (66) (SI Materials and Methods).
Phylogenetic Analyses. Lentiviral pol genes were aligned by using clustalw (v2.1) (97) and analyzed by using PhyML v3.0 (98) (SI Materials and Methods).
Viral and Immunodiagnostics.
Quantitative and qualitative analyses of virus, antibodies, and cells were performed as described (SI Materials and Methods).
Molecular Modeling. Structural analysis was performed by using PyMOL (99) and Molprobity (45, (100) (101) (102) . Mutants for rhCD4 or residue 375 were generated in silico by using the mutagenesis tool in PyMOL (SI Materials and Methods).
Statistical Analyses. Unpaired t and Fisher exact tests and Spearman rank correlations were calculated by using Prism 6 software (SI Materials and Methods).
